Still, the business noted that individual insurance represents a small part of operating income . An interview with Dr Chhatwal NPR: Pricey Hepatitis C Tablet Shreds Drug Industry Product sales Record The launch of Sovaldi, the $1,000-a-day tablet for hepatitis C, is normally shaping up as the most successful ever. In December THE MEALS and Medication Administration approved the pill. And Gilead Sciences was off to the races then. The company said it sold $2.27 billion worth of Sovaldi in the one fourth that ended March 31. $2.27 billion! The boffo number beat Wall Street's estimate for the quarter by a lot more than $1 billion . PBS NewsHour: New Hepatitis-C Drug Raises Wish At A Hefty Price A new drug includes a 90 to 100 % potential for curing the Hepatitis-C virus, but costs thousands of dollars for a course of treatment.An increase in the corrected QT interval was noticed among patients in the ZS-9 group through the initial phase, which was consistent with the reduction in serum potassium amounts and was dose-related. Mean raises in the QTc interval ranged from 0.03 msec at the cheapest ZS-9 dose to 7.61 msec at the highest ZS-9 dose on research day time 2, and from 0.38 msec at the lowest ZS-9 dosage to 10.3 msec at the best ZS-9 dose on research day 3. Little, clinically nonsignificant reduces in the mean QTc interval were noted in each ZS-9 dosage group on day 15. Through the initial phase, one patient receiving 10 g of ZS-9 had an increase of 71 msec in the QTc interval, which resulted in a QTc interval of 516 msec on day 3 while the individual was receiving concomitant treatment with ciprofloxacin .